Dilley Meredith A, Lee Joyce P, Broyles Ana Dioun
Division of Immunology at Boston Children's Hospital, Boston, Massachusetts.
Department of Pharmacy at Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26306. Epub 2016 Oct 27.
Reports of hypersensitivity reactions (HSRs) to MTX are limited to single case studies. We retrospectively reviewed HSRs to MTX during a 12-year period in our tertiary care pediatric center. Seven patients were evaluated for HSRs to MTX. Skin testing was positive in one of the four patients tested. One patient underwent successful graded challenge to MTX. Seventeen desensitizations to MTX were successfully performed in the other six patients. Skin testing, graded challenge, and desensitization were safe and effective procedures in the evaluation and management of patients with HSRs to MTX in our pediatric population.
关于甲氨蝶呤(MTX)过敏反应(HSRs)的报告仅限于单个病例研究。我们回顾性地研究了在我们三级护理儿科中心12年期间对MTX的过敏反应。对7例患者进行了MTX过敏反应评估。4例接受检测的患者中有1例皮肤试验呈阳性。1例患者成功进行了MTX分级激发试验。另外6例患者成功进行了17次MTX脱敏治疗。在我们儿科人群中,皮肤试验、分级激发试验和脱敏治疗是评估和管理MTX过敏反应患者的安全有效的方法。